Acquired Pure Red Cell Aplasia and Recombinant Erythropoietin
| Autor: | Sandip K Panda, Somanath Padhi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Nephrology
medicine.medical_specialty Acquired Pure Red Cell Aplasia Anemia business.industry Pure red cell aplasia Review Article medicine.disease Diseases of the genitourinary system. Urology Pathophysiology recombinant erythropoietin pure red cell aplasia Internal medicine Immunology Diagnosis medicine RC870-923 Recombinant erythropoietin business Clinical syndrome Kidney disease |
| Zdroj: | Indian Journal of Nephrology Indian Journal of Nephrology, Vol 31, Iss 4, Pp 331-335 (2021) |
| ISSN: | 1998-3662 0971-4065 |
| Popis: | Recombinant erythropoietin (rEPO)-associated immunologically driven acquired pure red cell aplasia (PRCA) is an underreported, potentially worsening clinical syndrome in the setting of treatment of anemia of chronic kidney disease. Most cases reported in world literature are related to different formulations of erythropoiesis-stimulating agents with an implication in diagnosis and management. This brief review highlights the clinical guidelines of rEPO usage in nephrology practice, the pathophysiologic mechanism of PRCA, clinical features, diagnosis, and suggested management protocols. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|